490 related articles for article (PubMed ID: 26688003)
1. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
2. FcRL4
Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
[TBL] [Abstract][Full Text] [Related]
3. Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study.
Seror R; Nocturne G; Lazure T; Hendel-Chavez H; Desmoulins F; Belkhir R; Ravaud P; Benbijja M; Poirier-Colame V; Taoufik Y; Mariette X
Arthritis Res Ther; 2015 Sep; 17(1):241. PubMed ID: 26336930
[TBL] [Abstract][Full Text] [Related]
4. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
[TBL] [Abstract][Full Text] [Related]
5. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
[TBL] [Abstract][Full Text] [Related]
6. Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF.
Carubbi F; Cipriani P; Di Benedetto P; Ruscitti P; Alunno A; Gerli R; Giacomelli R
Clin Exp Rheumatol; 2016; 34(6):1123-1124. PubMed ID: 27494407
[No Abstract] [Full Text] [Related]
7. NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment.
Pontarini E; Sciacca E; Grigoriadou S; Rivellese F; Lucchesi D; Fossati-Jimack L; Coleby R; Chowdhury F; Calcaterra F; Tappuni A; Lewis MJ; Fabris M; Quartuccio L; Bella SD; Bowman S; Pitzalis C; Mavilio D; De Vita S; Bombardieri M
Front Immunol; 2021; 12():706737. PubMed ID: 34594326
[TBL] [Abstract][Full Text] [Related]
8. The Transcriptome of Paired Major and Minor Salivary Gland Tissue in Patients With Primary Sjögren's Syndrome.
Verstappen GM; Gao L; Pringle S; Haacke EA; van der Vegt B; Liefers SC; Patel V; Hu Y; Mukherjee S; Carman J; Menard LC; Spijkervet FKL; Vissink A; Bootsma H; Kroese FGM
Front Immunol; 2021; 12():681941. PubMed ID: 34295332
[TBL] [Abstract][Full Text] [Related]
9. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
10. Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren's syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?
Blokland SLM; Hillen MR; Wichers CGK; Zimmermann M; Kruize AA; Radstake TRDJ; Broen JCA; van Roon JAG
RMD Open; 2019; 5(1):e000701. PubMed ID: 30713717
[No Abstract] [Full Text] [Related]
11. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
Pontarini E; Fabris M; Quartuccio L; Cappeletti M; Calcaterra F; Roberto A; Curcio F; Mavilio D; Della Bella S; De Vita S
Rheumatology (Oxford); 2015 Aug; 54(8):1429-34. PubMed ID: 25740829
[TBL] [Abstract][Full Text] [Related]
12. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
St Clair EW; Levesque MC; Prak ET; Vivino FB; Alappatt CJ; Spychala ME; Wedgwood J; McNamara J; Moser Sivils KL; Fisher L; Cohen P;
Arthritis Rheum; 2013 Apr; 65(4):1097-106. PubMed ID: 23334994
[TBL] [Abstract][Full Text] [Related]
14. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome.
Lavie F; Miceli-Richard C; Quillard J; Roux S; Leclerc P; Mariette X
J Pathol; 2004 Apr; 202(4):496-502. PubMed ID: 15095277
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome.
Daridon C; Devauchelle V; Hutin P; Le Berre R; Martins-Carvalho C; Bendaoud B; Dueymes M; Saraux A; Youinou P; Pers JO
Arthritis Rheum; 2007 Apr; 56(4):1134-44. PubMed ID: 17393395
[TBL] [Abstract][Full Text] [Related]
16. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome.
Daridon C; Pers JO; Devauchelle V; Martins-Carvalho C; Hutin P; Pennec YL; Saraux A; Youinou P
Arthritis Rheum; 2006 Jul; 54(7):2280-8. PubMed ID: 16802367
[TBL] [Abstract][Full Text] [Related]
17. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome.
Ittah M; Miceli-Richard C; Eric Gottenberg J; Lavie F; Lazure T; Ba N; Sellam J; Lepajolec C; Mariette X
Arthritis Res Ther; 2006; 8(2):R51. PubMed ID: 16507175
[TBL] [Abstract][Full Text] [Related]
18. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.
Ciccia F; Guggino G; Rizzo A; Alessandro R; Carubbi F; Giardina A; Cipriani P; Ferrante A; Cannizzaro A; Giacomelli R; Triolo G
Rheumatology (Oxford); 2014 Jul; 53(7):1313-20. PubMed ID: 24602921
[TBL] [Abstract][Full Text] [Related]
19. Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjögren's syndrome.
Gandolfo S; De Vita S
Clin Exp Rheumatol; 2019; 37 Suppl 118(3):199-208. PubMed ID: 31464677
[TBL] [Abstract][Full Text] [Related]
20. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.
Cornec D; Devauchelle-Pensec V; Tobón GJ; Pers JO; Jousse-Joulin S; Saraux A
J Autoimmun; 2012 Sep; 39(3):161-7. PubMed ID: 22749831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
